Back

Symptoms trend in patients with obstructive hypertrophic cardiomyopathy treated with disopyramide.

31 August 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Hypertrophic and other cardiomyopathies: miscellaneous findings Treatment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Felice Borrelli

Federico II University Hospital, Napoly (Italy)

9 More presentations in this session

Presentation thumbnail
Sex-based differences in anatomical and hemodynamic parameters and outcomes in patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation
Doctor A. Damlin (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and burden of non-obstructive hypertrophic cardiomyopathy: a real-world survey in Italy and Spain
Miss M. Lowe (Macclesfield, GB)
Abstract Slides Video
Presentation thumbnail
Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: observations from a tertiary care center
Doctor M. Desai (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Amplicon-based long-read sequencing is useful for confirming zygosity of DSG2 variants associated with Japanese ARVC.
Doctor K. Sonoda (Suita, JP)
Abstract Slides Video
Presentation thumbnail
Relationship between six-minute walk distance and cardiopulmonary exercise testing in non-obstructive hypertrophic cardiomyopathy
Doctor A. Bakalakos (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic and other cardiomyopathies: miscellaneous findings

The Event

Event poster

ESC Congress 2024

31 August 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy
thumbnail
Congress Session
Contemporary management of hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Systematic evaluation of serial electrocardiographic changes in patients treated with mavacamten

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources